Your session is about to expire
← Back to Search
Tepotinib +/- Osimertinib for Brain Cancer
Study Summary
This trial will assess the safety and efficacy of tepotinib in patients with brain tumors and MET alterations. The study will be conducted in two parts, with the first part exploring different doses of the drug and the second part expanding upon the most promising dose from the first part.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Group B
- Group 2: Group A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree can tepotinib and osimertinib be relied upon for the preservation of human health?
"Our team assessed the safety of tepotinib plus osimertinib to be a 1, owing to its Phase 1 status and limited evidence in regards to efficacy and safety."
Are there still opportunities to enroll in this research endeavor?
"At the current moment, this research is not looking for participants. Initially published on April 30th 2023 and last updated July 18th 2022, it may still be possible to find other trials related to brain cancer as 408 studies are actively recruiting or 104 if you specifically need treatment with tepotinib plus osimertinib."
Is this research a groundbreaking endeavor?
"Since 2013, when AstraZeneca first sponsored a study involving 603 patients, tepotinib plus osimertinib has been the focus of ongoing research. This combination drug was eventually approved for Phase 1 & 2 use and is currently part of 104 active trials in over 1000 cities across 51 nations."
Could you explain what other research has been done on the combination of tepotinib and osimertinib?
"Presently, there are 104 trials in progress studying the effects of tepotinib plus osimertinib. Of those studies, 17 have reached Phase 3 and many are based out of Uniondale New york. Across the world, 4878 sites are running these clinical tests."
What is the current enrollment for this medical trial?
"Unfortunately, this medical trial is not currently open to recruitment. The research was originally posted on April 30th 2023 and the most recent edition of its listing was made July 18th 2022. For those seeking alternative studies, there are 408 brain cancer trials in progress as well as 104 related to tepotinib plus osimertinib that are actively admitting patients."
Share this study with friends
Copy Link
Messenger